The world's largest medical technology company, Medtronic has a presences in more than 120 countries. Offering innovative therapies, Medtronic aided more than 8 million people last year with cardiac and vascular diseases, diabetes, and neurological and musculoskeletal conditions.
The Medtronic Endovascular Therapies R&D group was looking to understand the in-vivo performance and surgical delivery of stent grafts to further optimize device behavior for better patient outcomes.
Using Abaqus FEA and advanced probabilistic computational tools in Isight, engineers were able to identify key parameters, input manufacturing tolerances and variability, and improve stent component performance, which was then verified to be in good agreement with physical test results simulating a regulated 10-year-life product performance requirement.
Realistic simulation in conjunction with automated workflows enabled the Medtronic team to identify the stent graft device’s most important parameters and reduce stent design cycle time to a minimum while increasing design reliability to further benefit patients.